HA Concentration: 24 mg/ml (Medical-grade)

Lidocaine HCl: 0.3% (3 mg/ml)

Cross-linking Rate: 9%

Particle Size: 400 µm

Morphology: Monophasic, 3D structural network

Elastic Modulus (G’): 350 Pa

Extrusion Force: 12-15 N (Constant delivery)

Endotoxin Level: ≤ 0.05 EU/ml

Residual BDDE: < 0.1 ppm (Below detection limit)

pH / Osmolality: 7.0 ± 0.2 / 300 mOsmol/kg

Purification System: UPHEC™ (Ultra Precision & High Efficiency Cross-linking). 8-stage dialysis and double sterilization.

Efficacy Data (2023 KDA Multi-center Trial, N=320): 89% volume maintenance at 12 months; 74% retention observed at 18 months.

Clinical Protocol

• • Target Area: Mid-to-deep dermal augmentation, Subdermal layer (2-6mm depth).
• • Indications: Nasolabial folds, marionette lines, chin contouring, deep rhytides.
• • Dosage: 0.2 – 0.5 ml per injection site.
• • Instrument: 27G ½” Ultra-Thin Wall (UTW) tapered needle.

Specifications

• ✓ Volume: 1.1 ml sterile pre-filled syringe.
• ✓ Certification: CE0482, ISO 13485.
• ✓ Traceability: Batch-tracked vial with dual QR labels.
• ✓ Storage: 2-25°C. Protect from light. Do not freeze. Shelf life: 24 months.

Clinical Disclaimer: Contraindicated for superficial dermal injection, peri-orbital areas, or active inflammation sites. Clinical outcomes present a 15-22% variance depending on patient metabolism and baseline tissue volume. Administration strictly restricted to certified medical practitioners following anatomical assessment.